Clinical features of the series
| . | Screening set . | Test set (n = 240 patients) . | ||||
|---|---|---|---|---|---|---|
| Training . | P . | Validation . | Relative risk of death, OS (95%CI) . | Relative risk of progression, PFS (95% CI) . | ||
| Number of patients | 36 | 123 | 117 | |||
| IPI factors | ||||||
| Age, y | .004 | 2.406 (1.298-4.462); P = .005 | 1.238 (0.758-2.021); P = .394 | |||
| ≤ 60 | 13 | 61 | 35 | |||
| > 60 | 23 | 62 | 79 | |||
| Stage | .5 | 2.221 (1.213-4.067); P = .01 | 3.287 (1.823-5.927); P = .000 | |||
| I-II | 8 | 55 | 43 | |||
| III-IV | 28 | 68 | 65 | |||
| Lactate dehydrogenase | .112 | 3.13 (1.53-6.43); P = .001 | 3.051 (1.66-5.608); P = .000 | |||
| low | 10 | 56 | 28 | |||
| high | 26 | 67 | 55 | |||
| Performance status | .87 | 2.265 (1.306-3.929); P = .004 | 1.956 (1.182-3.238); P = .009 | |||
| Ambulatory (0-1) | 29 | 90 | 56 | |||
| Not ambulatory (2-4) | 7 | 33 | 22 | |||
| Extranodal site involvement | .49 | 2.012 (1.135-3.565); P = .017 | 2.197 (1.315-3.670); P = .003 | |||
| ≤ 1 site | 28 | 96 | 57 | |||
| > 1 site | 8 | 27 | 21 | |||
| IPI score (number of IPI factors) | .067 | 1.690 (1.378-2.073); P = .000 | 1.479 (1.244-1.758); P = .000 | |||
| Low risk (0,1) | 6 | 46 | 33 | |||
| Low to intermediate risk (2) | 10 | 24 | 25 | |||
| Intermediate to high risk (3) | 12 | 29 | 26 | |||
| High risk (4,5) | 8 | 22 | 28 | |||
| . | Screening set . | Test set (n = 240 patients) . | ||||
|---|---|---|---|---|---|---|
| Training . | P . | Validation . | Relative risk of death, OS (95%CI) . | Relative risk of progression, PFS (95% CI) . | ||
| Number of patients | 36 | 123 | 117 | |||
| IPI factors | ||||||
| Age, y | .004 | 2.406 (1.298-4.462); P = .005 | 1.238 (0.758-2.021); P = .394 | |||
| ≤ 60 | 13 | 61 | 35 | |||
| > 60 | 23 | 62 | 79 | |||
| Stage | .5 | 2.221 (1.213-4.067); P = .01 | 3.287 (1.823-5.927); P = .000 | |||
| I-II | 8 | 55 | 43 | |||
| III-IV | 28 | 68 | 65 | |||
| Lactate dehydrogenase | .112 | 3.13 (1.53-6.43); P = .001 | 3.051 (1.66-5.608); P = .000 | |||
| low | 10 | 56 | 28 | |||
| high | 26 | 67 | 55 | |||
| Performance status | .87 | 2.265 (1.306-3.929); P = .004 | 1.956 (1.182-3.238); P = .009 | |||
| Ambulatory (0-1) | 29 | 90 | 56 | |||
| Not ambulatory (2-4) | 7 | 33 | 22 | |||
| Extranodal site involvement | .49 | 2.012 (1.135-3.565); P = .017 | 2.197 (1.315-3.670); P = .003 | |||
| ≤ 1 site | 28 | 96 | 57 | |||
| > 1 site | 8 | 27 | 21 | |||
| IPI score (number of IPI factors) | .067 | 1.690 (1.378-2.073); P = .000 | 1.479 (1.244-1.758); P = .000 | |||
| Low risk (0,1) | 6 | 46 | 33 | |||
| Low to intermediate risk (2) | 10 | 24 | 25 | |||
| Intermediate to high risk (3) | 12 | 29 | 26 | |||
| High risk (4,5) | 8 | 22 | 28 | |||
Distribution of IPI factors in the whole series is shown. The χ2 test was used to assess differences in the proportions of individual prognostic factors between the training and validation sets of patients. Relative risk of event (OS and PFS) estimated from univariate Cox regression is shown for each IPI factor in the test set of patients.